Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
601-620 of 1,743 trials

Advanced Solid Tumors: Selpercatinib Access Program

We are providing access to selpercatinib for adults with locally advanced or metastatic solid tumors that have specific genetic changes. This program aims to help patients who may benefit from this targeted treatment.

Various Types of Cancer>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Hepatocellular Carcinoma: Durvalumab and Bevacizumab Study

We are studying whether the combination of durvalumab and bevacizumab can help prevent cancer recurrence in patients with hepatocellular carcinoma after surgery or ablation. This trial compares these treatments to a placebo to assess their effectiveness.

Early Stage Liver Cancer>2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteHepatologyOncology

Acute Respiratory Distress Syndrome: PRS CK STORM Treatment

We are testing a new cell therapy to see if it helps patients with acute respiratory distress syndrome caused by viruses like COVID-19 and influenza. The study will evaluate its safety and effectiveness in reducing severe immune responses.

Acute Respiratory Distress Syndrome (ARDS)>2 yearsSafety phase (I)Infectious DiseasesPulmonology

B-Cell Non-Hodgkin Lymphoma: Glofitamab Treatment

We are studying a new treatment using Glofitamab after Obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Our goal is to evaluate its safety and effectiveness compared to standard treatments.

B-cell Non-Hodgkin's Lymphoma Refractory>2 yearsSafety phase (I)HematologyOncology

Hemophilia A: Long-Term Follow-Up of BMN 270

We are investigating the long-term safety and effects of a gene therapy for severe hemophilia A in individuals who participated in a previous study. This includes looking at their quality of life and the need for additional treatments.

Hemophilia A>2 yearsMonitoring phase (IV)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Multiple Myeloma: BGB-11417 Treatment Study

We are investigating the safety and effectiveness of BGB-11417 alone and with other medications for patients with relapsed or refractory multiple myeloma. This study aims to find the best treatment options for those with a specific genetic marker.

Relapsed or Refractory Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Pancreatic Cancer: Islet Cell Transplantation After Surgery

We are studying the effects of removing part or all of the pancreas and transplanting the patient's own islet cells in patients with pancreatic cancer at high risk for complications. The goal is to see if this approach improves safety and quality of life.

Pancreatic Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Advanced Cancers: MAQ-001 Treatment Study

We are evaluating the safety of MAQ-001, both alone and with other treatments, for patients with advanced cancers. This study aims to understand how well it works in this patient group.

Advanced Cancers Treated with Immune Checkpoint Blockade>2 yearsSafety phase (I)Oncology

MK-1084 with Pembrolizumab for Metastatic Lung Cancer

We are studying a new treatment combination for patients with KRAS G12C-mutant metastatic lung cancer. The goal is to see if it works better than standard treatment in improving survival and quality of life.

Non-small cell lung cancer>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementOncology

Peripheral T-Cell Lymphoma: New Drug Combinations

We are studying whether combining Beleodaq or Folotyn with standard chemotherapy is more effective for newly diagnosed patients with Peripheral T-Cell Lymphoma. The goal is to see if these combinations improve treatment outcomes compared to standard therapy alone.

Peripheral T-Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Linvoseltamab for Relapsed or Refractory AL Amyloidosis

We are studying whether linvoseltamab is safe and effective for adults with relapsed or refractory systemic light chain amyloidosis. The trial will help us understand its impact on blood response and overall health.

Relapsed or Refractory Systemic Light Chain Amyloidosis>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyInternal Medicine

Immunoglobulin A Nephropathy: Ravulizumab Study

We are testing whether ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy. The study will also assess safety and quality of life compared to a placebo.

Immunoglobulin A Nephropathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Triple-Negative Breast Cancer: 68Ga-FAPI-46 PET/CT Imaging Study

We are investigating whether a new imaging method can predict how well early-stage high-risk triple-negative breast cancer patients respond to chemotherapy and immunotherapy. This may help tailor treatments more effectively.

Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyOtolaryngology

Severe Systemic Lupus Erythematosus: Belimumab and Rituximab Study

We are investigating whether combining belimumab with rituximab can improve treatment outcomes for people with severe systemic lupus erythematosus. This study will compare this combination to standard treatments to see if it better reduces harmful autoantibodies and improves overall health.

Systemic Lupus Erythematosus>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

ANCA-Associated Vasculitis: Rituximab with Cyclophosphamide

We are studying the effects of combining rituximab with cyclophosphamide compared to rituximab alone in patients with ANCA-associated vasculitis. This research aims to find out how these treatments help maintain remission and their impact on patient health.

ANCA Vasculitis>2 yearsMonitoring phase (IV)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementRheumatology

Multiple Sclerosis: Ifenprodil Study

We are investigating whether Ifenprodil can help repair nerve damage in people with Multiple Sclerosis. This study aims to see if it may improve symptoms and overall function.

Multiple Sclerosis>2 yearsSafety phase (I)Efficacy phase (II)Neurology

Esophageal Strictures: Budesonide Tablets

We are studying whether budesonide tablets can help prevent esophageal strictures in adults after cancer surgery. This trial compares two doses of the medication to a placebo to assess effectiveness and safety.

Oesophageal Cancer and Related Conditions>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesGastroenterologyOncology

Multiple Myeloma: Etentamig Injection Study

We are investigating the safety and effectiveness of a new injectable treatment for patients with relapsed or refractory Multiple Myeloma. This study aims to understand how well it works compared to existing therapies.

Relapsed or Refractory Multiple Myeloma>2 yearsSafety phase (I)Oncology

Ovarian Cancer: Raludotatug Deruxtecan Study

We are studying a new drug for patients with platinum-resistant, high-grade ovarian cancer. The goal is to see if it works better than current treatment options.

Ovarian and Related Cancers>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Scabies Treatment: Comparing Permethrin Creams

We are testing whether a new 10% permethrin cream works better than the standard 5% cream for treating scabies. We will also look at the safety of the new cream.

Scabies>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyInfectious Diseases